Literature DB >> 2521803

Identification of activated T cells and the suppressor/inducer subset in patients suffering from severe aplastic anemia.

U Köller1, W Hinterberger, L Gschwandtler, R Grümayer, O Majdic, W Knapp.   

Abstract

In patients with severe aplastic anemia (SAA), lymphocyte subpopulations were examined for the presence of HLA-DR and 2H4 (suppressor/inducer subset) antigen-expressing cells by flow cytometric analysis. Investigations were performed on peripheral blood lymphocytes before and after therapy with antithymocyte globulin (ATG) and methylprednisolone (MP), as well as on bone-marrow lymphocytes before therapy. Before treatment, only the absolute numbers of CD4+ T cells and the CD4+HLA-DR+/CD8+HLA-DR+ activated T cell ratio were significantly decreased (p less than 0.01 and p less than 0.001, respectively). Following successful ATG/MP treatment, a decrease in the CD4+/CD8+ T cell ratio was found. Regarding the suppressor/inducer subset, only absolute numbers of CD4+/2H4+ cells were somewhat higher in treated patients; the percentages were the same in all groups of patients. Studies performed on bone-marrow lymphocytes showed significantly decreased percentages of CD4+ and CD8+ T lymphocytes, which also express HLA-DR antigen. No significant changes in the distribution of activated T cells following ATG/MP therapy were found, suggesting that these cells play no major role in the pathogenesis of the disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2521803     DOI: 10.1007/bf00320231

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  40 in total

1.  Analysis of leukocyte differentiation antigens in blood and bone marrow from preleukemia (refractory anemia) patients using monoclonal antibodies.

Authors:  P Hokland; G Kerndrup; J D Griffin; J Ellegaard
Journal:  Blood       Date:  1986-04       Impact factor: 22.113

2.  Kinetics of activation antigen expression by in vitro-stimulated human T lymphocytes.

Authors:  W Holter; O Majdic; K Liszka; H Stockinger; W Knapp
Journal:  Cell Immunol       Date:  1985-02       Impact factor: 4.868

3.  Antithymocyte globulin treatment in patients with aplastic anemia: a prospective randomized trial.

Authors:  R Champlin; W Ho; R P Gale
Journal:  N Engl J Med       Date:  1983-01-20       Impact factor: 91.245

Review 4.  Immunosuppressive treatment of aplastic anemia as an alternative treatment for bone marrow transplantation.

Authors:  E Gluckman; A Marmont; B Speck; E C Gordon-Smith
Journal:  Semin Hematol       Date:  1984-01       Impact factor: 3.851

5.  Treatment of severe aplastic anaemia with antilymphocyte globulin or bone-marrow transplantation.

Authors:  B Speck; A Gratwohl; C Nissen; U Leibundgut; D Ruggero; B Osterwalder; H P Burri; P Cornu; M Jeannet
Journal:  Br Med J (Clin Res Ed)       Date:  1981-03-14

6.  Further evidence for lymphokine overproduction in severe aplastic anemia.

Authors:  W Hinterberger; G Adolf; G Aichinger; R Dudczak; K Geissler; P Höcker; C Huber; P Kalhs; W Knapp; U Köller
Journal:  Blood       Date:  1988-07       Impact factor: 22.113

7.  In vitro tests for distinguishing possible immune-mediated aplastic anemia from transfusion-induced sensitization.

Authors:  B J Torok-Storb; C Sieff; R Storb; J Adamson; E D Thomas
Journal:  Blood       Date:  1980-02       Impact factor: 22.113

8.  Lymphocytes of haemophilia patients treated with clotting factor concentrates display activation-linked cell-surface antigens.

Authors:  U Köller; O Majdic; K Liszka; H Stockinger; I Pabinger-Fasching; K Lechner; W Knapp
Journal:  Clin Exp Immunol       Date:  1985-03       Impact factor: 4.330

9.  Phenotype of peripheral blood lymphocytes in patients with progressive systemic sclerosis: activated T lymphocytes and the effect of D-penicillamine therapy.

Authors:  B Freundlich; S A Jimenez
Journal:  Clin Exp Immunol       Date:  1987-08       Impact factor: 4.330

10.  Abnormal distribution of the helper-inducer and suppressor-inducer T-lymphocyte subsets in the rheumatoid joint.

Authors:  C Pitzalis; G Kingsley; J Murphy; G Panayi
Journal:  Clin Immunol Immunopathol       Date:  1987-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.